Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 185

1.

Open-path cavity ring-down methane sensor for mobile monitoring of natural gas emissions.

Mchale LE, Martinez B, Miller TW, Yalin AP.

Opt Express. 2019 Jul 8;27(14):20084-20097. doi: 10.1364/OE.27.020084.

PMID:
31503758
2.

Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.

Miller TW, Traphagen NA, Li J, Lewis LD, Lopes B, Asthagiri A, Loomba J, De Jong J, Schiff D, Patel SH, Purow BW, Fadul CE.

J Neurooncol. 2019 Aug 9. doi: 10.1007/s11060-019-03258-0. [Epub ahead of print]

PMID:
31399936
3.

Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.

Miller TW, Amason JD, Garcin ED, Lamy L, Dranchak PK, Macarthur R, Braisted J, Rubin JS, Burgess TL, Farrell CL, Roberts DD, Inglese J.

PLoS One. 2019 Jul 5;14(7):e0218897. doi: 10.1371/journal.pone.0218897. eCollection 2019.

4.

Estrogen therapy induces an unfolded protein response to drive cell death in ER+ breast cancer.

Hosford SR, Shee K, Wells JD, Traphagen NA, Fields JL, Hampsch RA, Kettenbach AN, Demidenko E, Miller TW.

Mol Oncol. 2019 Aug;13(8):1778-1794. doi: 10.1002/1878-0261.12528. Epub 2019 Jul 9.

5.

Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier.

Chen Y, Wang Y, Salas LA, Miller TW, Mark K, Marotti JD, Kettenbach AN, Cheng C, Christensen BC.

Breast Cancer Res. 2019 Jan 25;21(1):14. doi: 10.1186/s13058-018-1090-z.

6.

Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing.

Shee K, Muller KE, Marotti J, Miller TW, Wells WA, Tsongalis GJ.

Am J Pathol. 2019 May;189(5):956-965. doi: 10.1016/j.ajpath.2018.08.020. Epub 2018 Oct 29. Review.

PMID:
30385093
7.

High-Precision Single-Molecule Characterization of the Folding of an HIV RNA Hairpin by Atomic Force Microscopy.

Walder R, Van Patten WJ, Ritchie DB, Montange RK, Miller TW, Woodside MT, Perkins TT.

Nano Lett. 2018 Oct 10;18(10):6318-6325. doi: 10.1021/acs.nanolett.8b02597. Epub 2018 Sep 24.

PMID:
30234311
8.

Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER+ breast cancer.

Shee K, Jiang A, Varn FS, Liu S, Traphagen NA, Owens P, Ma CX, Hoog J, Cheng C, Golub TR, Straussman R, Miller TW.

FASEB J. 2019 Feb;33(2):1644-1657. doi: 10.1096/fj.201801241R. Epub 2018 Aug 30.

PMID:
30161001
9.

Data obtained with a novel approach to estimate installment loan acquisition costs.

Lukongo OEB, Miller TW.

Data Brief. 2018 Apr 12;18:1257-1266. doi: 10.1016/j.dib.2018.04.027. eCollection 2018 Jun.

10.

Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer.

Yang W, Schwartz GN, Marotti JD, Chen V, Traphagen NA, Gui J, Miller TW.

Oncotarget. 2018 Jan 15;9(10):8810-8822. doi: 10.18632/oncotarget.24256. eCollection 2018 Feb 6.

11.

Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy.

Floros KV, Lochmann TL, Hu B, Monterrubio C, Hughes MT, Wells JD, Morales CB, Ghotra MS, Costa C, Souers AJ, Boikos SA, Leverson JD, Tan M, Serra V, Koblinski JE, Arribas J, Prat A, Paré L, Miller TW, Dozmorov MG, Harada H, Windle BE, Scaltriti M, Faber AC.

Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):E2594-E2603. doi: 10.1073/pnas.1717820115. Epub 2018 Feb 23.

12.

Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer.

Shee K, Yang W, Hinds JW, Hampsch RA, Varn FS, Traphagen NA, Patel K, Cheng C, Jenkins NP, Kettenbach AN, Demidenko E, Owens P, Faber AC, Golub TR, Straussman R, Miller TW.

J Exp Med. 2018 Mar 5;215(3):895-910. doi: 10.1084/jem.20171818. Epub 2018 Feb 7.

13.

Trailblazing Precision Oncology for Rare Tumor Subtypes.

Shee K, Miller TW.

Oncologist. 2018 Feb;23(2):143-144. doi: 10.1634/theoncologist.2017-0494. Epub 2017 Nov 20. No abstract available.

14.

Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor-positive breast cancer.

Yang W, Hosford SR, Traphagen NA, Shee K, Demidenko E, Liu S, Miller TW.

FASEB J. 2018 Mar;32(3):1222-1235. doi: 10.1096/fj.201700477R. Epub 2018 Jan 3.

15.

P-Rex1 Expression in Invasive Breast Cancer in relation to Receptor Status and Distant Metastatic Site.

Marotti JD, Muller KE, Tafe LJ, Demidenko E, Miller TW.

Int J Breast Cancer. 2017;2017:4537532. doi: 10.1155/2017/4537532. Epub 2017 Jun 15.

16.

Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer.

Hampsch RA, Shee K, Bates D, Lewis LD, Désiré L, Leblond B, Demidenko E, Stefan K, Huang YH, Miller TW.

Oncotarget. 2017 Mar 28;8(13):21806-21817. doi: 10.18632/oncotarget.15586.

17.

Maximizing the Benefit-Cost Ratio of Anthracyclines in Metastatic Breast Cancer: Case Report of a Patient with a Complete Response to High-Dose Doxorubicin.

Shee K, Kono AT, D'Anna SP, Seltzer MA, Lu X, Miller TW, Chamberlin MD.

Case Rep Oncol. 2016 Dec 8;9(3):840-846. doi: 10.1159/000453608. eCollection 2016 Sep-Dec. Erratum in: Case Rep Oncol. 2017 Feb 2;10 (1):152.

18.

Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER+ Breast Cancer.

Hosford SR, Dillon LM, Bouley SJ, Rosati R, Yang W, Chen VS, Demidenko E, Morra RP Jr, Miller TW.

Clin Cancer Res. 2017 Jun 1;23(11):2795-2805. doi: 10.1158/1078-0432.CCR-15-2764. Epub 2016 Nov 30.

19.

The PREX1/Rac signaling axis: Potential as a biomarker and therapeutic target in breast cancer.

Dillon LM, Miller TW.

Mol Cell Oncol. 2015 Apr 30;2(3):e996016. doi: 10.1080/23723556.2014.996016. eCollection 2015 Jul-Sep.

20.

Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.

Chamberlin MD, Bernhardt EB, Miller TW.

J Cell Biochem. 2016 Nov;117(11):2454-63. doi: 10.1002/jcb.25590. Epub 2016 Jun 3. Review.

21.

Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers.

Muller KE, Marotti JD, de Abreu FB, Peterson JD, Miller TW, Chamberlin MD, Tsongalis GJ, Tafe LJ.

Exp Mol Pathol. 2016 Jun;100(3):421-5. doi: 10.1016/j.yexmp.2016.04.002. Epub 2016 Apr 16.

PMID:
27095739
22.

Secreted Thrombospondin-1 Regulates Macrophage Interleukin-1β Production and Activation through CD47.

Stein EV, Miller TW, Ivins-O'Keefe K, Kaur S, Roberts DD.

Sci Rep. 2016 Jan 27;6:19684. doi: 10.1038/srep19684.

23.

Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.

Yang W, Hosford SR, Dillon LM, Shee K, Liu SC, Bean JR, Salphati L, Pang J, Zhang X, Nannini MA, Demidenko E, Bates D, Lewis LD, Marotti JD, Eastman AR, Miller TW.

Clin Cancer Res. 2016 May 1;22(9):2250-60. doi: 10.1158/1078-0432.CCR-15-2276. Epub 2016 Jan 5.

24.

CD47 Receptor Globally Regulates Metabolic Pathways That Control Resistance to Ionizing Radiation.

Miller TW, Soto-Pantoja DR, Schwartz AL, Sipes JM, DeGraff WG, Ridnour LA, Wink DA, Roberts DD.

J Biol Chem. 2015 Oct 9;290(41):24858-74. doi: 10.1074/jbc.M115.665752. Epub 2015 Aug 26.

25.

Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.

Tafe LJ, Gorlov IP, de Abreu FB, Lefferts JA, Liu X, Pettus JR, Marotti JD, Bloch KJ, Memoli VA, Suriawinata AA, Dragnev KH, Fadul CE, Schwartz GN, Morgan CR, Holderness BM, Peterson JD, Tsongalis GJ, Miller TW, Chamberlin MD.

Oncologist. 2015 Sep;20(9):1011-8. doi: 10.1634/theoncologist.2015-0097. Epub 2015 Jul 23.

26.

CD47-dependent regulation of H₂S biosynthesis and signaling in T cells.

Kaur S, Schwartz AL, Miller TW, Roberts DD.

Methods Enzymol. 2015;555:145-68. doi: 10.1016/bs.mie.2014.11.023. Epub 2015 Jan 8.

PMID:
25747479
27.

The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.

Bean JR, Hosford SR, Symonds LK, Owens P, Dillon LM, Yang W, Shee K, Schwartz GN, Marotti JD, Muller KE, Rosenkranz KM, Barth RJ, Chen VS, Agarwal VR, Miller TW.

Breast Cancer Res Treat. 2015 Jan;149(1):69-79. doi: 10.1007/s10549-014-3201-6. Epub 2014 Dec 10.

28.

Estrogen receptor alpha and androgen receptor are commonly expressed in well-differentiated liposarcoma.

Ingram DR, Dillon LM, Lev DC, Lazar A, Demicco EG, Eisenberg BL, Miller TW.

BMC Clin Pathol. 2014 Oct 22;14:42. doi: 10.1186/1472-6890-14-42. eCollection 2014.

29.

P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.

Dillon LM, Bean JR, Yang W, Shee K, Symonds LK, Balko JM, McDonald WH, Liu S, Gonzalez-Angulo AM, Mills GB, Arteaga CL, Miller TW.

Oncogene. 2015 Jul 23;34(30):3968-76. doi: 10.1038/onc.2014.328. Epub 2014 Oct 6.

30.

Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.

Hosford SR, Miller TW.

Pharmgenomics Pers Med. 2014 Aug 6;7:203-15. doi: 10.2147/PGPM.S52762. eCollection 2014. Review.

31.

Spatial, ontogenetic and interspecific variability in stable isotope ratios of nitrogen and carbon of Merluccius capensis and Merluccius paradoxus off South Africa.

Van Der Lingen CD, Miller TW.

J Fish Biol. 2014 Aug;85(2):456-72. doi: 10.1111/jfb.12436. Epub 2014 Jun 17.

PMID:
24934316
32.

Therapeutic targeting of cancers with loss of PTEN function.

Dillon LM, Miller TW.

Curr Drug Targets. 2014 Jan;15(1):65-79.

33.

Managing breast cancers with low estrogen receptor and HER2 by drugging both.

Miller TW.

Clin Cancer Res. 2014 Feb 1;20(3):528-30. doi: 10.1158/1078-0432.CCR-13-2994. Epub 2013 Dec 18.

34.

Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer.

Balko JM, Schwarz LJ, Bhola NE, Kurupi R, Owens P, Miller TW, Gómez H, Cook RS, Arteaga CL.

Cancer Res. 2013 Oct 15;73(20):6346-58. doi: 10.1158/0008-5472.CAN-13-1385. Epub 2013 Aug 21.

35.
36.

Endocrine resistance: what do we know?

Miller TW.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e37. Review.

37.

Who possesses drug resistance genes in the aquatic environment?: sulfamethoxazole (SMX) resistance genes among the bacterial community in water environment of Metro-Manila, Philippines.

Suzuki S, Ogo M, Miller TW, Shimizu A, Takada H, Siringan MA.

Front Microbiol. 2013 Apr 30;4:102. doi: 10.3389/fmicb.2013.00102. eCollection 2013.

38.

Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation.

Miller TW, Kaur S, Ivins-O'Keefe K, Roberts DD.

Matrix Biol. 2013 Aug 8;32(6):316-24. doi: 10.1016/j.matbio.2013.02.009. Epub 2013 Mar 13.

39.

Global trophic position comparison of two dominant mesopelagic fish families (Myctophidae, Stomiidae) using amino acid nitrogen isotopic analyses.

Choy CA, Davison PC, Drazen JC, Flynn A, Gier EJ, Hoffman JC, McClain-Counts JP, Miller TW, Popp BN, Ross SW, Sutton TT.

PLoS One. 2012;7(11):e50133. doi: 10.1371/journal.pone.0050133. Epub 2012 Nov 28.

40.

Synthesis and characterization of lithium oxonitrate (LiNO).

Switzer CH, Miller TW, Farmer PJ, Fukuto JM.

J Inorg Biochem. 2013 Jan;118:128-33. doi: 10.1016/j.jinorgbio.2012.09.022. Epub 2012 Oct 6.

41.

Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer.

Fox EM, Arteaga CL, Miller TW.

Front Oncol. 2012 Oct 16;2:145. doi: 10.3389/fonc.2012.00145. eCollection 2012.

42.

Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.

Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, Miller TW, Arteaga CL, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F.

Clin Cancer Res. 2012 Oct 15;18(20):5816-28. doi: 10.1158/1078-0432.CCR-12-1141. Epub 2012 Aug 29.

43.

Inhibitory signaling through signal regulatory protein-α is not sufficient to explain the antitumor activities of CD47 antibodies.

Soto-Pantoja DR, Miller TW, Frazier WA, Roberts DD.

Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):E2842; author reply E2844-5. doi: 10.1073/pnas.1205441109. Epub 2012 Aug 24. No abstract available.

44.

Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification.

Balko JM, Mayer IA, Sanders ME, Miller TW, Kuba MG, Meszoely IM, Wagle N, Garraway LA, Arteaga CL.

Mol Cancer Ther. 2012 Oct;11(10):2301-5. doi: 10.1158/1535-7163.MCT-12-0511. Epub 2012 Aug 9.

45.

CD47 deficiency confers cell and tissue radioprotection by activation of autophagy.

Soto-Pantoja DR, Miller TW, Pendrak ML, DeGraff WG, Sullivan C, Ridnour LA, Abu-Asab M, Wink DA, Tsokos M, Roberts DD.

Autophagy. 2012 Nov;8(11):1628-42. doi: 10.4161/auto.21562. Epub 2012 Aug 9.

46.

Membrane-initiated estrogen signaling: oncogenic or impotent?

Miller TW.

Expert Rev Endocrinol Metab. 2012 Jul;7(4):411-413. doi: 10.1586/eem.12.26.

PMID:
30754162
47.

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.

Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, González-Angulo AM, Mills GB, Pinto JA, Gómez HL, Arteaga CL.

Nat Med. 2012 Jul;18(7):1052-9. doi: 10.1038/nm.2795.

48.

Initiating breast cancer by PIK3CA mutation.

Miller TW.

Breast Cancer Res. 2012 Feb 7;14(1):301.

49.

The matricellular protein thrombospondin-1 globally regulates cardiovascular function and responses to stress via CD47.

Roberts DD, Miller TW, Rogers NM, Yao M, Isenberg JS.

Matrix Biol. 2012 Apr;31(3):162-9. doi: 10.1016/j.matbio.2012.01.005. Epub 2012 Jan 14. Review.

50.

The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium.

Balko JM, Miller TW, Morrison MM, Hutchinson K, Young C, Rinehart C, Sánchez V, Jee D, Polyak K, Prat A, Perou CM, Arteaga CL, Cook RS.

Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):221-6. doi: 10.1073/pnas.1115802109. Epub 2011 Dec 16.

Supplemental Content

Loading ...
Support Center